CRF buys Entra to boost healthcare remote monitoring and analytics
August 9, 2016
A complete wireless system for clinical data collection should be the result of CRF Health’s acquisition of Entra Health, a specialist in mobile health IT, cloud-based remote monitoring, health data exchange and analytics.
This will come from inter-connectivity between California-based CRF Health's TrialMax electronic clinical outcome assessment technology (eCOA) and Pennsylvania company Entra Health's cloud platform and mobile health devices.
The acquisition expands CRF Health's offerings into the expanding market of wireless medical and wellness devices, bringing connectivity to its eCOA technologies and establishing a complete network to collect, manage and analyse biometric and clinical trial data.
The combination solidifies CRF Health as a provider of eCOA and medical devices for remote patient monitoring, telemedicine and wireless health, backed by expertise and regulatory know-how.
The acquisition formalises an existing relationship, enabling both companies to bring their products to customers as an end-to-end integrated offering.
"This acquisition represents a significant step in our growth and enables us to deliver our solutions to a wider market with the backing of CRF Health's global infrastructure," said Richard Strobridge, CEO of Entra Health. "The combination of the two companies will bring new opportunities for Entra Health's talented team and will allow us to strengthen our operational capabilities and invest in enhancing our technology into the future. Our customers benefit from being part of one of the most well-respected names in the industry, bringing a global support network and access to specialised expertise."
Headquartered in San Diego, Entra Health provides EntraCare, a flexible and scalable remote monitoring product. EntraCare has regulatory approval and is used by patients in more than 50 countries.
Entra Health's FDA-cleared MyHealthPoint platform provides an integrated, secure and scalable system for collecting and analysing biometric data across a variety of wellness and clinical devices. It delivers remote monitoring of clinical trial and non-trial patient populations across a multitude of therapeutic areas as well as post-surgical, preventative and chronic care.
The company also manufactures the MyGlucoHealth brand of wireless blood glucose meters, and is a supplier of wireless glucose monitoring for clinical trials in diabetes research.
"We see tremendous promise in the opportunities the acquisition of Entra Health brings, as well as the contribution this makes to our continued growth strategy as we broaden CRF Health's reach across the industry,” said CRF Health's CEO Rachael Wyllie. “Combining CRF Health's extensive global eCOA and electronic informed consent expertise with Entra Health's clinical platform, medical device innovation and regulatory insight, we can now offer selection, production and delivery of devices together with the complete integration of data. CRF Health is now positioned to build upon our patient-centric approach, bringing new levels of connectivity to devices and cloud services much in demand from our customers."